Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence...
Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence that its Factor VIIa-CTP hemophilia therapy can be administered with an injection as well as intravenously. Providing the clotting agent via an injection would facilitate its prophylactic use by patients as a way to prevent bleeding rather than just for when a bleeding episode occurs. Prolor Biotech hopes to start two clinical trials for the treatment next year. (PR)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs